Skip to main content

Table 3 Adverse events

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

  Tofacitinib (n = 161) Baricitinib (n = 81) P value
All Events, n (%) 32 (19.9) 17 (21.0) 0.866
Infection 20 (12.4) 11 (13.6) 0.840
Herpes zoster 9 (5.6) 4 (4.9)  
Pneumonia 6 (3.7) 1 (1.2)  
Upper respiratory infection 4 (2.5) 3 (3.7)  
Callus infection   1 (1.2)  
Cytomegalovirus infection   1 (1.2)  
Fungus infection 1 (0.6)   
Sepsis   1 (1.2)  
Gastrointestinal disorder 6 (3.7) 2 (2.5) 0.720
Gastric ulcer   1 (1.2)  
Nausea 4 (2.5) 1 (1.2)  
Diarrhea 2 (1.2)   
Neoplasm 3 (1.9) 1 (1.2) > 0.999
Breast cancer   1 (1.2)  
Colon cancer 1 (0.6)   
Skin cancer 1 (0.6)   
Lung cancer 1 (0.6)   
Others 3 (1.9) 3 (3.7) 0.405
Hair loss 1 (0.6)   
Vertigo 1 (0.6) 1 (1.2)  
Headache   1 (1.2)  
Interstitial pneumonia 1 (0.6)   
Elevation of creatine kinase   1 (1.2)